Legal Opinion
Amgen Inc. v. Amneal Pharm. LLC
District Court, D. Delaware
Decided July 26, 2018No. Civ. No. 16-853-MSGPublishedCited by 3 opinions
1Opinion of the Court
GOLDBERG, M., District Judge
I. INTRODUCTION
This is a consolidated patent infringement action arising under the Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355, also known as the Hatch-Waxman Act. United States Patent No. 9,375,405 (the "'405 patent") is assigned to Plaintiff Amgen Inc. ("Amgen") and listed in the Approved Drug Products with Therapeutic Equivalents (the "Orange Book") as covering Sensipar®. Amgen accuses multiple Defendants of infringing the '405 patent by filing Abbreviated New Drug Applications ("ANDAs") seeking FDA approval to manufacture,…
2Cases cited26 opinions
- MARKMAN Et Al. v. WESTVIEW INSTRUMENTS, INC., Et Al.Supreme Court of the United States · 1996
- Herbert Markman and Positek, Inc. v. Westview Instruments, Inc. And Althon Enterprises, Inc.Court of Appeals for the Federal Circuit · 1995
- Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.Supreme Court of the United States · 2002
- Carl B. Bai v. L & L Wings, Inc., D/B/A Wings, and Great World Co. Of New York Ltd., and Elufa Fashions, Inc.Court of Appeals for the Federal Circuit · 1998
- Exergen Corp. v. Wal-Mart Stores, Inc.Court of Appeals for the Federal Circuit · 2009
21 more not listed; retrieve them via the Exa API.
3Cited by3 opinions
- Amgen Inc. v. Amneal Pharmaceuticals LLCCourt of Appeals for the Federal Circuit · 2020
- Cipla Ltd v. Amgen IncCourt of Appeals for the Third Circuit · 2019
- UFCW Local 1500 Welfare Fund v. Amgen Inc.District Court, D. Delaware · 2022